Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Pozycja w akcjach #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Cena akcji
$5.54
Ostatnia synchronizacja: 2024-09-18
Kapitalizacja rynkowa
$38.76M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel Alimera Sciences, Inc. (ALIM)

Kategoria

Zyski dla Alimera Sciences, Inc. (ALIM)
Zyski w Jun 2024 TTM: $-14.71M
Według najnowszych raportów finansowych Alimera Sciences, Inc., obecny zysk firmy wynosi $-14.71M. W roku 2022 firma osiągnęła zysk w wysokości $-18.08M, spadek w porównaniu do zysku z roku 2021, który wynosił $-3.93M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Alimera Sciences, Inc. od 2006 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-14.71M -26.61%
2023 $-20.05M 10.89%
2022 $-18.08M 359.56%
2021 $-3.93M -27.24%
2020 $-5.41M -47.13%
2019 $-10.23M -37.17%
2018 $-16.28M -25.47%
2017 $-21.84M -33.83%
2016 $-33.00M 8.15%
2015 $-30.52M -14.61%
2014 $-35.74M -22.70%
2013 $-46.23M 134.12%
2012 $-19.75M -12.30%
2011 $-22.52M 32.74%
2010 $-16.96M -59.95%
2009 $-42.36M -30.03%
2008 $-60.54M 383.70%
2007 $-12.52M 20.64%
2006 $-10.37M 0.00%
Zyski podobnych firm lub konkurentów